In our second clinical trials update of 2024, taking in developments in life sciences research and development from early-stage onwards, we look at a wide range of announcements – from onco
Digital health company Click Therapeutics has won an FDA breakthrough device designation for CT-155, a digital therapeutic (DTx) for the negative symptoms of schizophrenia
Boehringer Ingelheim has signed a multi-target collaboration with China’s Suzhou Ribo Life Science and its Swedish unit Ribocure to develop treatments for non-alcoholic or
The FDA has started a priority review of Amgen’s tarlatamab for small cell lung cancer (SCLC), the lead drug in the company’s pipeline of bispecific T-cell engager (BiTE)
A digital approach to the care of patients with heart failure, developed by Boehringer Ingelheim and ORCHA, will be rolled out in the northwest of the UK by a primary care
In another example of the pharma industry embracing generative artificial intelligence (GenAI), Boehringer Ingelheim will use technology developed by IBM to rev up antibod